Replies to post #213378 on Biotech Values

[RockRat]

MGNX:

The ESMO abstract released yesterday for flotetuzumab (CD123xCD3) seemed very encouraging as it showed activity at the proper dose in 4/8 AML/MDS patients, including 2 CRi, 1 morphologic leukemia free state, and 1 patient with bone marrow blast reduction >50%.

The number of =>G3 tox events gave me pause, though. What about you?

Regards, RockRat